Table SVII. Treatment-emergent fungal infection adverse events by high-level group terms and preferred term in the constant[a] treatment groups from baseline to end of treatment (safety analysis set)

	Placebo			Ustekinumab			Brodalumab 140 mg Q2W			Brodalumab 210 mg Q2W		
	n (%)	E	E/100 PY	*n* (%)	E	E/100 PY	*n* (%)	E	E/100 PY	*n* (%)	E	E/100 PY
Period 1	*n* = 881; 200.2 PYE			*n* = 612; 139.5 PYE			*n* = 1,490; 342.3 PYE			*n* = 1,495; 344.4 PYE		
Fungal infectious disorders	9 (1.0)	9	4.5	6 (1.0)	7	5.0	17 (1.1)	17	5.0	37 (2.5)	41	11.9
Tinea pedis	0			1 (0.2)	1	0.7	2 (0.1)	2	0.6	10 (0.7)	11	3.2
Vulvovaginal mycotic infection	3 (0.3)	3	1.5	1 (0.2)	1	0.7	2 (0.1)	2	0.6	3 (0.2)	3	0.9
Oral candidiasis	0			0			3 (0.2)	3	0.9	3 (0.2)	3	0.9
Skin *Candida*	2 (0.2)	2	1.0	0			1 (0.1)	1	0.3	3 (0.2)	3	0.9
Tinea versicolour	2 (0.2)	2	1.0	1 (0.2)	1	0.7	1 (0.1)	1	0.3	1 (0.1)	1	0.3
Candida infection	0			0				0		4 (0.3)	4	1.2
Vulvovaginal candidiasis	0			0			3 (0.2)	3	0.9	1 (0.1)	1	0.3
Fungal infection	1 (0.1)	1	0.5	1 (0.2)	1	0.7	0			1 (0.1)	1	0.3
Fungal skin infection	0			2 (0.3)	3	2.2	0			1 (0.1)	1	0.3
Oesophageal candidiasis	0			0			2 (0.1)	2	0.6	1 (0.1)	1	0.3
Oral fungal infection	0			0			2 (0.1)	2	0.6	1 (0.1)	1	0.3
Genital candidiasis	0			0			0			2 (0.1)	2	0.6
Onychomycosis	0			0			0			2 (0.1)	2	0.6
Tinea cruris	0			0			1 (0.1)	1	0.3	1 (0.1)	1	0.3
Tinea infection	1 (0.1)	1	0.5	0			0			1 (0.1)	1	0.3
Body tinea	0			0			0			1 (0.1)	1	0.3
Dermatophytosis	0			0			0			1 (0.1)	1	0.3
Fungal oesophagitis	0			0			0			1 (0.1)	1	0.3
Gastritis fungal	0			0			0			0		
Meningitis cryptococcal	0			0			0			1 (0.1)	1	0.3
Upper respiratory fungal infection	0			0			0			1 (0.1)	1	0.3
Period 2				*n* = 612; 432.9 PYE			*n* = 467; 293.3 PYE			*n* = 537; 415.8 PYE		
Fungal infectious disorders				14 (2.3)	17	3.9	15 (3.2)	15	5.1	33 (6.1)	41	9.9
Tinea pedis				3 (0.5)	3	0.7	3 (0.6)	3	1.0	8 (1.5)	9	2.2
Oral candidiasis				1 (0.2)	2	0.5	4 (0.9)	4	1.4	8 (1.5)	8	1.9
Vulvovaginal candidiasis				1 (0.2)	1	0.2	3 (0.6)	3	1.0	3 (0.6)	4	1.0
Vulvovaginal mycotic infection				3 (0.5)	3	0.7	0			2 (0.4)	2	0.5
Fungal skin infection				2 (0.3)	4	0.9	0			2 (0.4)	3	0.7
Oral fungal infection				0			1 (0.2)	1	0.3	2 (0.4)	2	0.5
Tinea versicolour				2 (0.3)	2	0.5	0			1 (0.2)	1	0.2
Fungal infection				2 (0.3)	2	0.5	0			0		
Oesophageal candidiasis				0			1 (0.2)	1	0.3	1 (0.2)	1	0.2
Onychomycosis				0			0			2 (0.4)	2	0.5
Skin candida				0			1 (0.2)	1	0.3	1 (0.2)	2	0.5
Tinea cruris				0			0			2 (0.4)	2	0.5
Body tinea				0			1 (0.2)	1	0.3	0		
Candida infection				0			0			1 (0.2)	2	0.5
Coccidioidomycosis				0			0			1 (0.2)	1	0.2
Meningitis cryptococcal				0			0			1 (0.2)	1	0.2
Tinea manuum				0			1 (0.2)	1	0.5	0		
Upper respiratory fungal infection				0			0			1 (0.2)	1	0.2
Period 3							*n* = 467; 529.5 PYE			*n* = 537; 869.7 PYE		
Fungal infectious disorders							20 (4.3)	23	4.3	52 (9.7)	82	9.4
Oral candidiasis							4 (0.9)	5	0.9	16 (3.0)	20	2.3
Tinea pedis							4 (0.9)	4	0.8	11 (2.0)	16	1.8
Vulvovaginal candidiasis							3 (0.6)	3	0.6	4 (0.7)	6	0.7
Onychomycosis							2 (0.4)	2	0.4	4 (0.7)	4	0.5
Fungal skin infection							0			4 (0.7)	5	0.6
Oropharyngeal candidiasis							1 (0.2)	1	0.2	3 (0.6)	3	0.3
Vulvovaginal mycotic infection							0			4 (0.7)	4	0.5
Candida infection							0			3 (0.6)	5	0.6
Oral fungal infection							1 (0.2)	1	0.2	2 (0.4)	3	0.3
Skin candida							2 (0.4)	3	0.6	1 (0.2)	2	0.2
Tinea cruris							1 (0.2)	1	0.2	2 (0.4)	2	0.2
Tinea infection							0			3 (0.6)	3	0.3
Body tinea							1 (0.2)	1	0.2	1 (0.2)	1	0.1
Oesophageal candidiasis							1 (0.2)	1	0.2	1 (0.2)	1	0.1
Balanitis candida							0			1 (0.2)	1	0.1
Coccidioidomycosis							0			1 (0.2)	1	0.1
Dermatophytosis							0			1 (0.2)	1	0.1
Meningitis cryptococcal							0			1 (0.2)	1	0.1
Oropharyngitis fungal							0			1 (0.2)	1	0.1
Tinea manuum							1 (0.2)	1	0.2	0		
Tinea versicolour							0			1 (0.2)	1	0.1
Upper respiratory fungal infection							0			1 (0.2)	1	0.1

[a]Constant treatment groups included all patients exposed to the same planned treatment during the full length of a treatment period. Four time periods were identified: period 1, the initial double-blind, placebo- and ustekinumab-controlled 12-week induction phase; period 2, the ustekinumab-controlled 52-week period; and periods 3 and 4, which covered the open-label extension trials up to the end of treatment or last follow-up.
E: number of events; E/100 PY: event rate per 100 patient-years; PYE: patient-years of exposure; Q2W: every 2 weeks.